Skip to content
value.today

Ribon Therapeutics, Inc.

Total raised
$119 M
5 rounds on record
Latest round
$25 M
Dec 2022
First round on record
Nov 2015
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ribon Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$25 MNo. 5$10 to $50 million

Ribon Therapeutics, Inc.: Raise no. 5, Dec 2022

Investors in this round

1 investor had bought by the notice of Dec 22, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Sutton · Executive Officer
  • Paul Brannelly · Executive Officer
  • Prakash Raman · Executive Officer, Director
  • Cameron Wheeler · Director
  • Emma Reeve · Director
  • Eyal Lifschitz · Director
  • James Audia · Director
  • Jeff Goater · Director
  • Jodie Morrison · Director
  • Jonathan Root · Director
  • Laura Brass · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Prakash Raman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 22, 2022. Read the notice at the SEC.

equitySEC
Jun 2021$25 MNo. 4$10 to $50 million

Ribon Therapeutics, Inc.: Raise no. 4, Jun 2021

Investors in this round

16 investors had bought by the notice of Jun 14, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $60 M offered; $35 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward M. Stewart · Executive Officer
  • Victoria M. Richon · Executive Officer, Director
  • Cameron M. Wheeler · Director
  • Emma M. Reeve · Director
  • James M. Audia · Director
  • Jodie M. Morrison · Director
  • Jonathan M. Root · Director
  • Laura M. Brass · Director
  • Marian M. Nakada · Director
  • Svennilson Peter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victoria M. Richon, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 14, 2021. Read the notice at the SEC.

equitySEC
Dec 2018$25 MNo. 3$10 to $50 million

Ribon Therapeutics, Inc.: Raise no. 3, Dec 2018

Investors in this round

10 investors had bought by the notice of Jan 4, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $65 M offered; $40 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Cordo · Executive Officer
  • Victoria M. Richon · Executive Officer, Director
  • Anja M. Koenig · Director
  • Cameron M. Wheeler · Director
  • James M. Audia · Director
  • Jonathan M. Root · Director
  • Marian M. Nakada · Director
  • Svennilson Peter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victoria M. Richon, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2019. Read the notice at the SEC.

equitySEC
Oct 2017$20 MNo. 2$10 to $50 million

Ribon Therapeutics, Inc.: Raise no. 2, Oct 2017

Investors in this round

8 investors had bought by the notice of Oct 10, 2017: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Cordo · Executive Officer
  • Victoria M. Richon · Executive Officer, Director
  • Cameron M. Wheeler · Director
  • Jonathan M. Root · Director
  • Laurence Lasky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victoria M. Richon, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 10, 2017. Read the notice at the SEC.

equitySEC
Nov 2015$24 MNo. 1$10 to $50 million

Ribon Therapeutics, Inc.: Raise no. 1, Nov 2015

Investors in this round

5 investors had bought by the notice of Nov 23, 2016: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Victoria M. Richon · Executive Officer, Director
  • Cameron M. Wheeler · Director
  • Jonathan M. Root · Director
  • Laurence Lasky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victoria M. Richon, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 23, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ribon Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2022

That is all the official record says: Ribon Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Ribon Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 16 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ribon Therapeutics, Inc.
NameRoleNamed in
Gary SuttonExecutive officerDec 2022
Paul BrannellyExecutive officerDec 2022
Prakash RamanExecutive officerDec 2022
Edward M. StewartExecutive officerJun 2021
Victoria M. RichonExecutive officerJun 2021
David M. CordoExecutive officerJan 2019
Cameron WheelerDirectorDec 2022
Emma ReeveDirectorDec 2022
Eyal LifschitzDirectorDec 2022
James AudiaDirectorDec 2022
Jeff GoaterDirectorDec 2022
Jodie MorrisonDirectorDec 2022
Jonathan RootDirectorDec 2022
Laura BrassDirectorDec 2022
Prakash RamanDirectorDec 2022
Cameron M. WheelerDirectorJun 2021
Emma M. ReeveDirectorJun 2021
James M. AudiaDirectorJun 2021
Jodie M. MorrisonDirectorJun 2021
Jonathan M. RootDirectorJun 2021
Laura M. BrassDirectorJun 2021
Marian M. NakadaDirectorJun 2021
Svennilson PeterDirectorJun 2021
Victoria M. RichonDirectorJun 2021
Anja M. KoenigDirectorJan 2019
Laurence LaskyDirectorOct 2017
William M. HarringtonDirectorDec 2015